Chakravarty et al. (2026)
- Authors: Debanjana Chakravarty, Ravi Dandekar, Vishal D. Lashkari, Iris Tilton, Lindsay McAlpine, Jennifer Chiarella, Allison Nelson, Thomas Ngo, Michael R. Wilson, Samuel J. Pleasure, Serena Spudich
- Institutes: University of California, San Francisco (UCSF), San Francisco, CA, USA, Yale University School of Medicine, New Haven, CT, USA, Uniformed Services University of the Health Sciences, Bethesda, MD, USA, Infectious Diseases Clinical Research Program (IDCRP), Rockville, MD, USA
- Publisher: medRxiv
- Link: DOI
Summary
This research provides a significant update to the understanding of Long COVID by suggesting that ‘brain fog’ and other neurological symptoms are not caused by a single, universal autoimmune response. By demonstrating that patients’ immune profiles are as unique as their symptoms and often overlap with healthy controls, the study highlights the immense biological complexity of the condition. These findings suggest that a simple, one-size-fits-all diagnostic test for neurological Long COVID is unlikely to be effective. Instead, the results push the scientific community to move toward more personalized medicine and to explore other potential drivers such as neuroinflammation or metabolic issues.
What was researched?
The study investigated whether patients with neurological Long COVID (n-LC) and cognitive impairment share a common set of autoantibodies that target the central nervous system.
Why was it researched?
While previous studies suggested that the immune system might mistakenly attack the brain after a COVID-19 infection, earlier results were inconsistent and failed to prove if a single autoimmune mechanism was responsible for neurological symptoms across the patient population.
How was it researched?
Researchers performed a cross-cohort case-control analysis of 111 participants, examining cerebrospinal fluid and blood serum samples using mouse brain tissue staining and high-throughput phage immunoprecipitation sequencing (PhIP-Seq). The study compared n-LC patients against both pre-pandemic healthy controls and individuals who recovered from COVID-19 without lasting symptoms.
What has been found?
The researchers found no shared autoantibody signature that could reliably distinguish n-LC patients from healthy controls across the different study groups. Instead, the autoantibody targets were sparse and highly specific to individual patients rather than being common to the disease. Additionally, the frequency of antibody binding to brain tissue was found to be similar between patients and control participants.
Discussion
The findings suggest that neurological Long COVID is biologically diverse and likely involves multiple different mechanisms rather than a uniform antibody-mediated disease. The study’s strength lies in its use of two independent cohorts and comprehensive screening technologies, though it is limited to the specific antigens included in the testing library.
Conclusion & Future Work
The study concludes that there is no dominant, common CNS autoantibody-mediated mechanism for neurological Long COVID. This shift in understanding encourages future research to look beyond shared antibody targets and investigate more personalized or non-antibody-driven causes for post-COVID cognitive symptoms.